Loading
The PD-L1 antibody atezolizumab shrank tumours in about a quarter of patients with advanced alveolar soft part sarcoma, with responses lasting years in a disease resistant to chemotherapy, and became the first approved treatment for this sarcoma.
Phase 2 study of 52 patients aged 2 and older with advanced alveolar soft part sarcoma treated with atezolizumab every three weeks.
Objective response was 24 percent (37 percent in an updated analysis with longer follow-up), with a median duration of response of over 16 months and stable disease in most others; toxicity was typical of PD-L1 blockade and low grade.
Atezolizumab is the first-line systemic treatment for advanced alveolar soft part sarcoma, a rare, slow-growing but ultimately metastatic sarcoma of young adults for which chemotherapy never worked.
Shares Alveolar soft part sarcoma, Atezolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/